Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · USD

$19.3

+0.04 (+0.2%)· Recorded snapshot

Market cap	3.1B
Revenue (ttm)	3.6M
Net income (ttm)	-511.5M
EPS (ttm)	-$2.83
Shares out	159.8M
Volume	1,263,276
Beta	1.02

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.6M
Net income (ttm): -511.5M
EPS (ttm): -$2.83
Market cap: 3.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-54.9

P25 n/aP50 n/aP75 n/a

ROIC-333.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DNLI indicators

Market & fundamental data

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001714899
Company name	Denali Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	24823R105
Earnings date	2026-11-03
Earnings time	amc
Employees	507
Employees change	64
Employees growth	14.45%
Enterprise value	$2.2B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2013
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2017-12-08
Is primary listing	Yes
Is SPAC	No
ISIN number	US24823R1059
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.1B
Market cap category	Mid-Cap
Next earnings date	2026-11-03
Options	Yes
Price	$19.26
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	DNLI
U.S. state	California
Website	https://www.denalitherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-14.71%
EV/Sales	590.12x
FCF / EV yield	-20.57%
FCF yield	-14.44%
Forward EV/Sales	22.06x
Forward P/S	31.42x
P/B ratio	3.68x
P/S ratio	840.49x
Price / tangible book value	3.79x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-15,037.38%
Pretax margin	-14,188.37%
Profit per employee	$-1M
Revenue per employee	$7,108
ROA	-29.15%
ROA (5Y)	-17.79%
ROCE	-50.75%
ROE	-54.93%
ROE (5Y)	-31.43%
ROIC	-333.73%
SBC / revenue	2,638.4%
Tax / revenue	2.83%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Net income growth years	0
Revenue growth 3Y	-78.1%
Revenue growth 5Y	-60.12%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3.4M
Depreciation and amortization	$15.9M
EBIT	$-541.9M
EBITDA	$-526.1M
EPS	$-2.83
FCF per share	$-2.74
Financing cash flow	$425.4M
Free cash flow	$-437.5M
Free cash flow minus SBC	$-532.5M
Gross profit	$-397.2M
Income taxes	$102,000
Investing cash flow	$69M
Net borrowing	$-1.4M
Net cash flow	$60.3M
Net income	$-511.5M
Operating cash flow minus SBC	$-529.1M
Operating income	$-541.9M
Revenue	$3.6M
Stock-based compensation	$95.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.45
Book value per share	$5.23
Debt / equity	0.05
Long-term assets	$404M
Long-term liabilities	$232.7M
Net cash (debt)	$902.3M
Net cash / market cap	29.79%
Net cash growth	-2.92%
Net debt / equity	-1.08
Piotroski F-Score	1
Property, plant and equipment	$113.4M
Shareholders' equity	$835.2M
Tangible book value	$799.9M
Tangible book value per share	$5.01
Total assets	$1.2B
Total cash	$710.5M
Total debt	$37.7M
Total liabilities	$322.8M
WACC	9.76%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$753.9M
Current liabilities	$90.1M
Current ratio	8.37
Net working capital	$-36.4M
Quick ratio	7.95
Working capital	$663.8M
Working capital turnover	0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-5.8%
Dividend yield	0%
Shareholder yield	-5.8%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$21.50
1D price change	0.21%
1M price change	-6.82%
1M total return	-6.82%
1W price change	0.37%
1W total return	0.37%
1Y price change	17.21%
1Y return CAGR	17.23%
1Y total return	17.21%
20-day SMA	$18.89
200-day SMA	$21.22
3M price change	-19.39%
3M total return	-19.39%
3Y price change	4.4%
3Y return CAGR	1.44%
3Y total return	4.4%
50-day SMA	$20.88
50-day SMA vs 200-day SMA	50under200
52-week high	$27.30
52-week high date	2026-07-09
52-week low	$13.75
52-week low date	2025-11-07
5Y price change	-59.47%
5Y return CAGR	-16.53%
5Y total return	-59.47%
6M price change	-4.71%
6M total return	-4.71%
All-time high	$93.94
All-time high date	2020-12-22
All-time low	$10.57
All-time low date	2025-04-07
Average true range (ATR)	$0.77
Average volume	1.7M
Beta (1Y)	1.84
Beta (2Y)	1.91
Beta (5Y)	1.02
Change from 52-week high	-29.45%
Change from 52-week low	40.07%
Change from all-time high	-79.77%
Change from all-time low	79.75%
Change from open	1.37%
Day's gap	-1.14%
Dollar volume	$24.3M
High price	$19.26
Low price	$18.90
Monthly RSI	47.48
Open price	$19.00
Position in 52-week range	100%
Premarket change	0.1%
Premarket close	$19.22
Premarket price	$19.24
Premarket volume	5.4K
Previous close	$19.22
Price vs 150-day SMA	-11.62%
Price vs 20-day SMA	0.59%
Price vs 200-day SMA	-10.48%
Price vs 50-day SMA	-9.02%
Relative volume	0.73
RSI	46.05
Sharpe ratio	0.49
Sharpe ratio (3Y)	0.26
Sharpe ratio (5Y)	-0.03
Sortino ratio	0.83
Sortino ratio (3Y)	0.49
Sortino ratio (5Y)	0.04
Volume	1.3M
Weekly RSI	44.13
YTD price change	15.08%
YTD total return	15.08%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	155.1M
Float percentage	97.03%
Shares change (QoQ)	0.36%
Shares change (YoY)	5.8%
Shares held by insiders	2.97%
Shares held by institutions	99.87%
Shares outstanding	159.8M
Short % of float	9.98%
Short % of shares	9.68%
Short ratio	8.9 days

Deeper analysis on DNLI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DNLI report

Is a complete DNLI research report available?

No complete published report is available for Denali Therapeutics Inc. (DNLI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Denali Therapeutics Inc. (DNLI)

Price

Financial snapshot

Fair-value bridge

Latest news · DNLI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DNLI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DNLI

Frequently asked questions